{
    "clinical_study": {
        "@rank": "41699", 
        "arm_group": [
            {
                "arm_group_label": "Etoricoxib Prescription (Period 1)", 
                "description": "First Etoricoxib Prescription, Apr. 1, 2002 to Feb. 17, 2005"
            }, 
            {
                "arm_group_label": "Etoricoxib Prescription (Period 2)", 
                "description": "First Etoricoxib Prescription, Feb. 18, 2005 to Dec. 31, 2015"
            }, 
            {
                "arm_group_label": "Repeat Etoricoxib Prescription", 
                "description": "One prescription during the Period 1 and, at least, one etoricoxib prescription during Period 2."
            }
        ], 
        "brief_summary": {
            "textblock": "This postmarketing study was conducted to describe prescribing patterns for etoricoxib\n      (ARCOXIA\u00ae) in General Practice and describe the incidence of selected adverse events\n      recorded in the United Kingdom (UK) Medicines and Health Care Products Regulatory Agency\n      (MHRA) General Practice Research Database (GPRD)."
        }, 
        "brief_title": "Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Osteoarthritis", 
            "Rheumatoid Arthritis", 
            "Ankylosing Spondylitis", 
            "Gout", 
            "Arthritis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid", 
                "Gout", 
                "Osteoarthritis", 
                "Spondylitis", 
                "Spondylitis, Ankylosing"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  All patients in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one\n             electronic outpatient prescription record for etoricoxib issued by a General\n             Practitioner during the period (April 1, 2002 to December 31, 2015) at the date of\n             query execution against the FF-GPRD data warehouse.\n\n        Exclusion Criteria:\n\n          -  Not registered in a GPRD-contributing practice that had continuously\n\n        collected data deemed to be 'up-to-standard' for research purposes from 1 April 2002\n        through to 31 December 2015.\n\n          -  Never registered as a permanent patient of a General Practitioner in the practice\n\n          -  Registration details were not acceptable (i.e. incomplete data or logically\n             implausible dates)\n\n          -  Not registered with a General Practitioner for at least 365 days before the date that\n             the patient's first etoricoxib prescription was recorded in the GPRD"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "All participants in the MHRA's Full Feature GPRD (FF-GPRD) who have at least one\n        electronic outpatient prescription record for etoricoxib issued by a General Practitioner\n        during the period (April 1, 2002 to December 31, 2015) at the date of query execution\n        against the FF-GPRD data warehouse."
            }
        }, 
        "enrollment": {
            "#text": "30000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01685424", 
            "org_study_id": "0663-162", 
            "secondary_id": [
                "7013.021", 
                "EMEA/H/A - 31/632"
            ]
        }, 
        "intervention": {
            "arm_group_label": [
                "Etoricoxib Prescription (Period 1)", 
                "Etoricoxib Prescription (Period 2)", 
                "Repeat Etoricoxib Prescription"
            ], 
            "description": "As per routine clinical practice in the United Kingdom", 
            "intervention_name": "Etoricoxib", 
            "intervention_type": "Drug", 
            "other_name": "ARCOXIA\u00ae)"
        }, 
        "intervention_browse": {
            "mesh_term": "Etoricoxib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Etoricoxib", 
            "ARCOXIA", 
            "Osteoarthritis", 
            "Rheumatoid Arthritis", 
            "Ankylosing Spondylitis", 
            "Gout", 
            "Arthritis"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "number_of_groups": "3", 
        "official_title": "Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Dose of Initial Etoricoxib Prescription", 
                "safety_issue": "No", 
                "time_frame": "At first prescription (during a time period up to 13.75 years)"
            }, 
            {
                "measure": "Duration of Initial Etoricoxib Prescription", 
                "safety_issue": "No", 
                "time_frame": "At first prescription (during a time period up to 13.75 years)"
            }, 
            {
                "measure": "Participant's Baseline Characteristics (Demographics and Medical)", 
                "safety_issue": "No", 
                "time_frame": "At first prescription (during a time period up to 13.75 years)"
            }, 
            {
                "measure": "Incidence of Adverse Events of Special Interest Among Etoricoxib Users", 
                "safety_issue": "Yes", 
                "time_frame": "During a time period up to 13.75 years"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01685424"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "\"Off-label\" use of Etoricoxib", 
            "safety_issue": "No", 
            "time_frame": "At first prescription (during a time period up to 13.75 years)"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2006", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}